Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 0
---
Item 1. Financial Statements

CERO THERAPEUTICS HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

    March 31,  
    December 31, 

    2025  
    2024 

    (Unaudited)  

    ASSETS 

    Current assets: 

    Cash, restricted cash, and cash equivalents 
    $5,203,537  
    $3,327,060 
  
    Prepaid expenses and other current assets 
     564,464  
     274,749 
  
    Deferred offering costs 
     -  
     112,232 
  
    Total current assets 
     5,768,001  
     3,714,041 

    Deferred offering costs, net of current portion 
     500,000  
     500,000 
  
    Operating lease right-of-use assets 
     1,271,186  
     1,464,367 
  
    Property and equipment, net 
     452,227  
     528,521 
  
    Total assets 
    $7,991,414  
    $6,206,929 

    LIABILITIES AND STOCKHOLDERS’ DEFICIT 

    Current liabilities: 

    Accounts payable 
    $6,379,056  
    $4,507,318 
  
    Accrued liabilities 
     469,659  
     1,913,175 
  
    Operating lease liability 
     905,005  
     876,392 
  
    Earnout liability 
     20,000  
     20,000 
  
    Deemed dividend – common stock liability, 13,835 shares 
     85,500  
     85,500 
  
    Total current liabilities 
     7,859,220  
     7,402,385 

    Operating lease liability, net of current portion 
     461,580  
     699,107 
  
    Total liabilities 
     8,320,800  
     8,101,492 

    Commitments and contingencies 

    Stockholders’ deficit: 

    Series C convertible preferred stock, $0.0001 par value; 2,853 shares authorized; 2,537 and 2,853 issued and outstanding